2025-11-10

CoreTissue BioEngineering Raises New Funding of ¥600 Million: Nippon Ham and Mitsui Sumitomo Insurance Capital Join as New Shareholders

CoreTissue BioEngineering, Inc. has raised a total of approximately 600 million yen in funding. Two new shareholders have joined the company: MSIVC2025V Investment Limited Partnership, with Nippon Ham Ltd. and Mitsui Sumitomo Insurance Capital Co., Ltd. as general partners. Additional investments have also been made by existing shareholders: Waseda Innovation Fund No. 3 Investment Partnership and Waseda Investment Limited Partnership, with Well Investment Co., Ltd. as general partner; MMA Investment Limited Partnership, with More Management Co., Ltd. as general partner; and NextG Investment Limited Partnership, with KSP Inc. as general partner. CTBE conducted a first-in-human (FIH) trial in December of last year for a tissue-engineered ligament (CT-ACL001) for use in anterior cruciate ligament reconstruction surgery and is currently continuing with a pilot clinical trial to evaluate safety. With this latest funding, the company plans to proceed with preparations for clinical trials in the United States with the aim of expanding its business there, as well as to gain feasibility for mass production technology with the aim of commercializing the product, thereby accelerating its business.